| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c08bc64beefb2dbbb4a8b7f9123b3a2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
2000-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ac9de5c9343ebbc34295f14f4b617e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56efb4fbc688513df92f5a88f30eaf8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8380e05111c8203c4d076397e0c76a02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_027ac0a5c11b66985af44df9b994f442
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_651d5f1758171d163ca7eba5db743a4a |
| publicationDate |
2006-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6984621-B1 |
| titleOfInvention |
Wound contraction inhibitor |
| abstract |
The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1–5000 ng/ml, and more preferably 1–100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent. |
| priorityDate |
1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |